NCT00257881终止1 期
Phase 1 Dose-Escalation Study of Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors
Wyeth is now a wholly owned subsidiary of Pfizer2 个研究点 分布在 1 个国家目标入组 46 人开始时间: 2005年11月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 46
- 试验地点
- 2
- 主要终点
- Dose Limiting Toxicity, Adverse Event
研究概览
简要总结
The primary purpose of this study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of CMD-193 administered intravenously (IV) to subjects with advanced malignant tumors. The secondary purpose is to obtain preliminary information on the pharmacokinetics and antitumor activity of IV CMD-193.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 74 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Malignant solid tumor progressed, or no standard treatment available
- •Tumor expression of Lewis Y antigen
排除标准
- •Cancer therapy within 28 days before enrollment
- •Pregnant or breastfeeding women
- •Unstable or serious concurrent medical conditions
结局指标
主要结局
Dose Limiting Toxicity, Adverse Event
次要结局
- Pharmacokinetics parameters, Tumor assessment
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Safety Study of GPX-150 in Patients With Solid TumorsAdvanced Solid Tumors - Phase 1 PopulationNCT00710125Gem Pharmaceuticals27
已完成
1 期
Study Evaluating CMD-193 in Advanced Malignant Solid TumorsNeoplasmsNCT00161642Wyeth is now a wholly owned subsidiary of Pfizer54
已完成
1 期
A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic CarcinomaNeoplasms, LiverNCT00629759Jennerex Biotherapeutics14
终止
1 期
TKI258 in Subjects With Refractory or Relapsed Multiple MyelomaMultiple MyelomaNCT00243763Novartis64
已完成
1 期
Safety Study of Sterile Compound C31510 for Injection to Subjects with Solid TumorsSolid TumorsNCT01251562BPGbio50